Development of the first inner ear organoids by 3D bioprinting for pharmacological screening in hearing disorders: CTIBIOTECH™ announces strategic agreement with SATT AxLR and CILCARE

CTIBIOTECH™, a leading innovator in human tissue engineering and 3D bioprinting, is proud to announce its selection by SATT AxLR and CILCARE to support the development of the OrgaEar project. This strategic collaboration aims to create a world first: 3D bioprinted inner ear organoids from human induced pluripotent stem cells (hiPSC).

NEWSAWARDSINNOVATION

10/13/20252 min read

Lyon and Montpellier, France - October 9, 2025

•CTIBIOTECH™ has been selected by SATT AxLR and CILCARE to develop the OrgaEar project, a disruptive innovation in hearing disorders research.

•Hearing disorders are a growing public health crisis. The development of innovative therapeutic solutions is an urgent strategic priority.

•Facilitating a highly advanced non-animal New Approach Methods NAMs alternative in the hearing disorders sector, CTIBIOTECH™ strengthens its position at the forefront of a cell-based bioassay market estimated at 28 billion euros by 2028, CAGR > 7%).

CTIBIOTECH™, a leading innovator in human tissue engineering and 3D bioprinting, is proud to announce its selection by SATT AxLR and CILCARE to support the development of the OrgaEar project. This strategic collaboration aims to create a world first: 3D bioprinted inner ear organoids from human induced pluripotent stem cells (hiPSC).

This innovative project addresses a critical need in hearing disorders research by developing advanced pharmacological screening tools, positioned as intermediaries between traditional cell lines and animal models. The aim is to transpose and optimize the previously established protocol for obtaining inner ear organoids by integrating CTIBIOTECH™ 3D bioprinting technology, thus guaranteeing reproducibility, optimal quality and yield, and industrialization in the medium term to contribute to CILCARE's development and business.